Corvus Pharmaceuticals, Inc. CRVS
We take great care to ensure that the data presented and summarized in this overview for Corvus Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRVS
View all-
Orbimed Advisors LLC San Diego, CA7.17MShares$62.8 Million1.75% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct6.45MShares$56.6 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$30.4 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$28.7 Million16.52% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$23.5 Million0.26% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.23MShares$19.6 Million2.54% of portfolio
-
Foresite Capital Management Vi LLC Larkspur, CA1.73MShares$15.2 Million4.93% of portfolio
-
Geode Capital Management, LLC Boston, MA1.46MShares$12.8 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY1.44MShares$12.6 Million0.02% of portfolio
-
State Street Corp Boston, MA1.01MShares$8.83 Million0.0% of portfolio
Latest Institutional Activity in CRVS
Top Purchases
Top Sells
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Insider Transactions at CRVS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 27
2025
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
1,176,332
-14.1%
|
$4,705,328
$4.16 P/Share
|
|
Jun 27
2025
|
Orbimed Advisors LLC Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,397,684
+14.35%
|
$4,193,052
$3.5 P/Share
|
|
Jun 27
2025
|
Peter A. Thompson Director |
SELL
Open market or private sale
|
Indirect |
1,176,332
-14.1%
|
$4,705,328
$4.16 P/Share
|
|
Jun 27
2025
|
Peter A. Thompson Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,397,684
+14.35%
|
$4,193,052
$3.5 P/Share
|
|
Jun 04
2025
|
William Benton Jones |
BUY
Exercise of conversion of derivative security
|
Direct |
19,357
+10.06%
|
$58,071
$3.5 P/Share
|
|
May 07
2025
|
Richard A Md Miller President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
559,073
+32.97%
|
$1,677,219
$3.5 P/Share
|
|
May 10
2024
|
Richard A Md Miller President and CEO |
SELL
Bona fide gift
|
Indirect |
302,016
-20.27%
|
-
|
|
May 06
2024
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Direct |
577,634
+50.0%
|
$577,634
$1.73 P/Share
|
|
May 06
2024
|
William Benton Jones |
BUY
Open market or private purchase
|
Direct |
20,000
+11.51%
|
$20,000
$1.73 P/Share
|
|
May 15
2023
|
Linda Grais |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$20,000
$2.45 P/Share
|
|
Dec 20
2022
|
William Benton Jones |
BUY
Open market or private purchase
|
Direct |
20,000
+13.01%
|
$0
$0.79 P/Share
|
|
Dec 14
2022
|
Leiv Lea Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
4,000
+2.91%
|
$0
$0.84 P/Share
|
|
Dec 14
2022
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.67%
|
$0
$0.78 P/Share
|
|
Dec 13
2022
|
Leiv Lea Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
30,000
+18.84%
|
$0
$0.74 P/Share
|
|
Dec 13
2022
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Indirect |
50,000
+3.27%
|
$0
$0.74 P/Share
|
|
Sep 28
2022
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Indirect |
25,000
+1.76%
|
$0
$0.76 P/Share
|
|
Sep 20
2022
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.49%
|
$0
$0.82 P/Share
|
|
Jun 27
2022
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.37%
|
$5,000
$1.0 P/Share
|
|
Jun 24
2022
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.37%
|
$5,000
$1.03 P/Share
|
|
Jun 06
2022
|
Richard A Md Miller President and CEO |
BUY
Open market or private purchase
|
Indirect |
890
+0.07%
|
$890
$1.01 P/Share
|
Last 12 Months Summary
| Exercise of in-the-money or at-the-money derivatives securities | 2.8M shares |
|---|---|
| Exercise of conversion of derivative security | 578K shares |
| Open market or private sale | 2.35M shares |
|---|